Enhancing Participation in Clinical Trials
The FDA's December 2025 finalized guidance on Enhancing Participation in Clinical Trials calls on sponsors to design more inclusive, representative trials by broadening eligibility criteria, reducing participant and site burden, and adopting flexible, modern trial designs. Despite broad industry commitment to equitable research, sponsors and CROs continue to face systemic challenges including legacy exclusion criteria, difficulty quantifying burden in advance, and limited foresight into subgroup signals and enrollment timelines. ClinSphere® Trial IntelX™, powered by data from 80,000+ complete protocols and 40,000+ benchmarked trials, equips sponsors with AI-driven intelligence to address these challenges before they arise. By transforming cross-trial data into actionable prestart design guidance, Trial IntelX™ enables evidence-based eligibility decisions, quantifiable burden reduction, and strategic country and site placement that improves both representativeness and operational performance.
In this guide, you'll explore
- The FDA's December 2025 guidance reframes 'diversity' as representativeness, encompassing both demographic and non-demographic factors such as comorbidities, organ dysfunction, and extremes of body weight.
- ClinSphere® Trial IntelX™ leverages 80,000+ complete protocols and 40,000+ benchmarked trials to deliver AI-powered, prestart design intelligence that reduces participant and site burden.
- Protocol burden and complexity scoring surfaces artificially constrained inclusion criteria, enabling sponsors to simplify eligibility and expand trial access without compromising scientific integrity.
- The Country and Site Optimizer ranks geographies and Principal Investigators using historical performance, competitive intelligence, and demographic enrollment data to improve representativeness and accelerate enrollment.
- Portfolio-level forecasting models allow teams to set inclusive enrollment targets, evaluate subgroup detection feasibility, and build transparent, defensible plans aligned with FDA expectations before first patient in.